Skip to main content

Research Repository

Advanced Search

All Outputs (71)

Classification for long-term monitoring of cough. Case Study (2025)
Journal Article
den Brinker, A. C., Rietman, R., Ouweltjes, O., van Marion, M., Thackray-Nocera, S., Crooks, M. G., & Morice, A. H. (2025). Classification for long-term monitoring of cough. Case Study. Discover Artificial Intelligence, 5, Article 56. https://doi.org/10.1007/s44163-025-00264-2

For management of chronic respiratory diseases, unobtrusive longitudinal monitoring of cough has been proposed. Such a monitoring system was developed using a classifier trained on an initial observation period. After this initial period, a personali... Read More about Classification for long-term monitoring of cough. Case Study.

Complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): a feasibility, wait-list design randomised controlled trial (2025)
Journal Article
Crooks, M. G., Wright, C., Hart, S., Allgar, V., English, A., Swan, F., Dyson, J., Richardson, G., Twiddy, M., Cohen, J., Simpson, A., Huang, C., Sykes, D. L., & Johnson, M. (2025). Complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): a feasibility, wait-list design randomised controlled trial. BMJ Open Respiratory Research, 12(1), Article e002327. https://doi.org/10.1136/bmjresp-2024-002327

Introduction Breathlessness is common and impairs the quality of life of people with idiopathic pulmonary fibrosis (IPF) and non-IPF fibrotic interstitial lung diseases (ILD). We report the findings of a multicentre, fast-track (wait-list), mixed-met... Read More about Complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): a feasibility, wait-list design randomised controlled trial.

ERS guideline recommendation on airflow for breathlessness: the pitfalls of applying GRADE evidence ratings to complex non-pharmacological interventions (2025)
Journal Article
Luckett, T., Swan, F., Clark, J., Roberts, M., Pearson, M., Hutchinson, A., Currow, D., Kochovska, S., Crooks, M., Smith, T., & Johnson, M. (2025). ERS guideline recommendation on airflow for breathlessness: the pitfalls of applying GRADE evidence ratings to complex non-pharmacological interventions. European respiratory journal, 65(2), Article 2402244. https://doi.org/10.1183/13993003.02244-2024

Nighttime Cough Characteristics in Chronic Obstructive Pulmonary Disease Patients (2025)
Journal Article
den Brinker, A. C., Ouweltjes, O., Rietman, R., Thackray-Nocera, S., Crooks, M. G., & Morice, A. H. (2025). Nighttime Cough Characteristics in Chronic Obstructive Pulmonary Disease Patients. Sensors, 25(2), Article 404. https://doi.org/10.3390/s25020404

Coughing is a symptom of many respiratory diseases. An increased amount of coughs may signal an (upcoming) health issue, while a decreasing amount of coughs may indicate an improved health status. The presence of a cough can be identified by a cough... Read More about Nighttime Cough Characteristics in Chronic Obstructive Pulmonary Disease Patients.

Can Passive Cough Monitoring Predict COPD Exacerbations? (2025)
Journal Article
Morice, A. H., den Brinker, A. C., Crooks, M., Thackray-Nocera, S., Ouweltjes, O., & Rietman, R. (2025). Can Passive Cough Monitoring Predict COPD Exacerbations?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 22(1), Article 2487909. https://doi.org/10.1080/15412555.2025.2487909

Purpose: Validation of an alert mechanism for COPD exacerbations based on coughing detected by a stationary unobtrusive nighttime monitor. Methods: This prospective double-blind longitudinal study of cough monitoring included 40 chronic obstructive p... Read More about Can Passive Cough Monitoring Predict COPD Exacerbations?.

Exploring COPD patients’ and carers’ experiences, understandings and expectations of exacerbations: an interview study (2024)
Journal Article
Hutchinson, A., Russell, R., Cummings, H., Usmani, O., MacFadyen, S., Cohen, J., Morris, T., Muellerova, H., Xu, Y., Hellens, G., Roy, K., & Crooks, M. G. (2025). Exploring COPD patients’ and carers’ experiences, understandings and expectations of exacerbations: an interview study. BJGP Open, https://doi.org/10.3399/BJGPO.2024.0026

Background: Chronic Obstructive Pulmonary Disease (COPD) exacerbations are clinically significant events that affect millions globally.
Aim: To explore patients’ and carers’ experiences, understandings and responses to exacerbations.
Design and... Read More about Exploring COPD patients’ and carers’ experiences, understandings and expectations of exacerbations: an interview study.

Breathlessness without borders: a call to action for global breathlessness research (2024)
Journal Article
Clark, J. D., Binnie, K., Bond, M., Crooks, M., Currow, D. C., Curry, J., Elsey, H., Habib, M., Hutchinson, A., Soyiri, I., Johnson, M. J., Nair, S., Rao, S., Siqueira-Filha, N., Spathis, A., & Williams, S. (2024). Breathlessness without borders: a call to action for global breathlessness research. NPJ Primary Care Respiratory Medicine, 34(1), Article 26. https://doi.org/10.1038/s41533-024-00384-9

It is likely that the burden of breathlessness in low and middle-income countries (LMICs) is much higher than has been estimated using calculations of disease burden and expected prevalence of the symptom. However, most breathlessness research has be... Read More about Breathlessness without borders: a call to action for global breathlessness research.

Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England (2024)
Journal Article
Wang, H. I., Doran, T., Crooks, M. G., Khunti, K., Heightman, M., Gonzalez-Izquierdo, A., Qummer Ul Arfeen, M., Loveless, A., Banerjee, A., & Van Der Feltz-Cornelis, C. (2024). Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England. Journal of Infection, 89(4), Article 106235. https://doi.org/10.1016/j.jinf.2024.106235

Objectives: This study examines clinically confirmed long-COVID symptoms and diagnosis among individuals with COVID in England, aiming to understand prevalence and associated risk factors using electronic health records. To further understand long CO... Read More about Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England.

Correction to: Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites (npj Primary Care Respiratory Medicine, (2024), 34, 1, (6), 10.1038/s41533-024-00363-0) (2024)
Journal Article
Crooks, M. G., Cummings, H., Morice, A. H., Sykes, D., Brooks, S., Jackson, A., & Xu, Y. (2024). Correction to: Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites (npj Primary Care Respiratory Medicine, (2024), 34, 1, (6), 10.1038/s41533-024-00363-0). NPJ Primary Care Respiratory Medicine, 34(1), Article 19. https://doi.org/10.1038/s41533-024-00376-9

Correction to: npj Primary Care Respiratory Medicine34, 6 (2024) https://doi.org/10.1038/s41533-024-00363-0, published online 29 April 2024 In this article the Table 2 columns were incorrectly structured. The original article has been corrected.

Integrated care policy recommendations for complex multisystem long term conditions and long COVID (2024)
Journal Article
van der Feltz-Cornelis, C. M., Sweetman, J., Turk, F., Allsopp, G., Gabbay, M., Khunti, K., Williams, N., Montgomery, H., Heightman, M., Lip, G. Y., Crooks, M. G., Strain, W. D., Loveless, A., Hishmeh, L., Smith, N., & Banerjee, A. (2024). Integrated care policy recommendations for complex multisystem long term conditions and long COVID. Scientific reports, 14(1), Article 13634. https://doi.org/10.1038/s41598-024-64060-1

The importance of integrated care for complex, multiple long term conditions was acknowledged before the COVID pandemic but remained a challenge. The pandemic and consequent development of Long COVID required rapid adaptation of health services to ad... Read More about Integrated care policy recommendations for complex multisystem long term conditions and long COVID.

Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD (2024)
Journal Article
Monk, P. D., Brookes, J. L., Tear, V. J., Batten, T. N., Newall, C., Mankowski, M., Crooks, M. G., Singh, D., Chaudhuri, R., Leaker, B., Lunn, K., Reynolds, S., Dudley, S., Gabbay, F. J., Holgate, S. T., Djukanovic, R., & Wilkinson, T. M. (2024). Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD. Respiratory Research, 25(1), Article 228. https://doi.org/10.1186/s12931-024-02854-7

Background: Respiratory viral infections are major drivers of chronic obstructive pulmonary disease (COPD) exacerbations. Interferon-β is naturally produced in response to viral infection, limiting replication. This exploratory study aimed to demonst... Read More about Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD.

Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites (2024)
Journal Article
Crooks, M. G., Cummings, H., Morice, A. H., Sykes, D., Brooks, S., Jackson, A., & Xu, Y. (2024). Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites. NPJ Primary Care Respiratory Medicine, 34(1), Article 6. https://doi.org/10.1038/s41533-024-00363-0

Short-acting beta-agonist (SABA) over-use in asthma is harmful for patients and the environment. The Investment and Impact Fund (IIF) 2022/2023 financially rewarded English primary care networks that achieved specific targets, including reducing SABA... Read More about Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites.

Accelarated immune ageing is associated with COVID-19 disease severity (2024)
Journal Article
Lord, J. M., Veenith, T., Sullivan, J., Sharma-Oates, A., Richter, A. G., Greening, N. J., McAuley, H. J., Evans, R. A., Moss, P., Moore, S. C., Turtle, L., Gautam, N., Gilani, A., Bajaj, M., Wain, L. V., Brightling, C., Raman, B., Marks, M., Singapuri, A., Elneima, O., …on behalf of the PHOSP-COVID Study collaborative group. (2024). Accelarated immune ageing is associated with COVID-19 disease severity. Immunity and Ageing, 21(1), Article 6. https://doi.org/10.1186/s12979-023-00406-z

Background: The striking increase in COVID-19 severity in older adults provides a clear example of immunesenescence, the age-related remodelling of the immune system. To better characterise the association between convalescent immunesenescence and ac... Read More about Accelarated immune ageing is associated with COVID-19 disease severity.

Effects of Azithromycin on Blood Inflammatory Gene Expression and Cytokine Production in Sarcoidosis (2024)
Journal Article
Fraser, S. D., Thackray-Nocera, S., Wright, C., Flockton, R., James, S. R., Crooks, M. G., Kaye, P. M., & Hart, S. P. (2024). Effects of Azithromycin on Blood Inflammatory Gene Expression and Cytokine Production in Sarcoidosis. Lung, https://doi.org/10.1007/s00408-024-00743-w

Introduction: In sarcoidosis granulomas, monocyte-derived macrophages are activated by pro-inflammatory cytokines including TNF and IL-6. Current drug treatment for sarcoidosis aims to suppress inflammation but disabling side effects can ensue. The m... Read More about Effects of Azithromycin on Blood Inflammatory Gene Expression and Cytokine Production in Sarcoidosis.

The Effect of Long-Term Azithromycin on Objective and Subjective Cough in Chronic Respiratory Disease: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Noncomparative Studies (2024)
Journal Article
Sykes, D. L., Mason, P., Rahunathan, N., Hart, S. P., Morice, A. H., & Crooks, M. G. (2024). The Effect of Long-Term Azithromycin on Objective and Subjective Cough in Chronic Respiratory Disease: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Noncomparative Studies. Lung, https://doi.org/10.1007/s00408-024-00729-8

Introduction: Azithromycin is an effective treatment for various respiratory conditions but its effect on cough is poorly understood. We synthesised data from randomised controlled trials (RCTs) and noncomparative studies (NCT) examining its effect o... Read More about The Effect of Long-Term Azithromycin on Objective and Subjective Cough in Chronic Respiratory Disease: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Noncomparative Studies.

Long COVID and cardiovascular disease: a prospective cohort study (2024)
Journal Article
Lawson, C. A., Moss, A. J., Arnold, J. R., Bagot, C., Banerjee, A., Berry, C., Greenwood, J., Hughes, A. D., Khunti, K., Mills, N. L., Neubauer, S., Raman, B., Sattar, N., Leavy, O. C., Richardson, M., Elneima, O., McAuley, H. J., Shikotra, A., Singapuri, A., Sereno, M., …on behalf of the PHOSP-COVID Study Collaborative Group. (2024). Long COVID and cardiovascular disease: a prospective cohort study. Open heart, 11(1), Article e002662. https://doi.org/10.1136/openhrt-2024-002662

Background Pre-existing cardiovascular disease (CVD) or cardiovascular risk factors have been associated with an increased risk of complications following hospitalisation with COVID-19, but their impact on the rate of recovery following discharge is... Read More about Long COVID and cardiovascular disease: a prospective cohort study.

Pathways to care for Long COVID and for long-term conditions from patients' and clinicians' perspective (2023)
Journal Article
Turk, F., Sweetman, J., Allsopp, G., Crooks, M., Cuthbertson, D. J., Gabbay, M., Hishmeh, L., Lip, G. Y., Strain, W. D., Williams, N., Wootton, D., Banerjee, A., & van der Feltz-Cornelis, C. (2023). Pathways to care for Long COVID and for long-term conditions from patients' and clinicians' perspective. Journal of Evidence-Based Medicine, 16(4), 435-437. https://doi.org/10.1111/jebm.12563

Examining the relationship between inflammatory biomarkers during COVID-19 hospitalization and subsequent long-COVID symptoms: A longitudinal and retrospective study (2023)
Journal Article
Sykes, D. L., Van der Feltz-Cornelis, C. M., Holdsworth, L., Hart, S. P., O'Halloran, J., Holding, S., & Crooks, M. G. (2023). Examining the relationship between inflammatory biomarkers during COVID-19 hospitalization and subsequent long-COVID symptoms: A longitudinal and retrospective study. Immunity, Inflammation and Disease, 11(10), Article e1052. https://doi.org/10.1002/iid3.1052

Introduction: Long-COVID is a heterogeneous condition with a litany of physical and neuropsychiatric presentations and its pathophysiology remains unclear. Little is known about the association between inflammatory biomarkers, such as interleukin-6 (... Read More about Examining the relationship between inflammatory biomarkers during COVID-19 hospitalization and subsequent long-COVID symptoms: A longitudinal and retrospective study.

A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2 (2023)
Journal Article
Wilkinson, T., De Soyza, A., Carroll, M., Chalmers, J. D., Crooks, M. G., Griffiths, G., Shankar-Hari, M., Ho, L. P., Horsley, A., Kell, C., Lara, B., Mishra, B., Moate, R., Page, C., Pandya, H., Raw, J., Reid, F., Saralaya, D., Scott, I. C., Siddiqui, S., …on behalf of The ACCORD Collaborative Group. (2023). A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2. ERJ Open Research, 9(5), Article 00249-2023. https://doi.org/10.1183/23120541.00249-2023

Background Increased serum interleukin (IL)-33 predicts poor outcomes in patients hospitalised with coronavirus disease 2019 (COVID-19). We examined the efficacy and safety of tozorakimab, a monoclonal antibody that neutralises IL-33, in improving ou... Read More about A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.